Posts Tagged ‘Medicines Company’

Review of this week’s snow-impacted ePharma Summit conference is now up on the blog!


Benicar for kiddies – Olmesartan medoxomil (Benicar), approved in 2002 to treat high blood pressure in adults, has been sanctioned by the U.S. Food and Drug Administration to treat the same condition in children aged 6 to 16, drug maker Daiichi Sankyo said Thursdaymore

Ouch. More cuts at The Medicines Co. – Medicines Co said it would cut 43 jobs, or 26 percent of its field-based workforce, by the end of February, and take a related charge of $3.5 million in the first quartermore

Billy Tauzin leaving as head of PhRMA – The head of the influential trade association for drug manufacturers announced Thursday night that he is leaving his job. The development comes amid uncertainty over the fate of President Barack Obama’s health care overhaul, which the drug association had backed after striking a deal with the White House and Senate Democrats to limit costs to the industry in the legislationmore

J&J launches new social media initiatives.


Social Media “listening” training and services – Getting started with a social media “listening” strategy? We can help by putting you in contact with the best providers. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


Visual treat – Out-of-this-world coral photos. Yum.


31 Awesome benches. Oddly amusing!


Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

FDA approves sharing unapproved drug uses with doctors. “The public health may be advanced by healthcare professionals’ receipt of medical journal articles … on unapproved new uses,” the agency states. Such uses may even “constitute a medically recognized standard of care,” according to the agency.

The Medicines Company to acquire TargantaTarganta’s lead product, oritavancin, is an innovative antibiotic with potent bactericidal (killing) activity against a broad range of gram-positive bacteria including staphylococcal strains with resistance to methicillin (MRSA) and vancomycin.

Roche to up the bid for GenentechGenentech stock rose from around $84 to around $86 on news that Roche is indeed going ahead with its bid to acquire the company. The FT reports Roche is look at $95 a share for the 44 percent of the company that it does not yet own. The timing of the bid will before early February…


Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Reblog this post [with Zemanta]

Read Full Post »